Sharon Cunningham, Shorla Pharma CEO

Shorla Phar­ma scores an ex­pe­dit­ed re­view for its mys­tery can­di­date to treat T-cell ma­lig­nan­cies

Since launch­ing Shorla Phar­ma three years ago to de­sign bet­ter ver­sions of ex­ist­ing can­cer drugs, co-founders Sharon Cun­ning­ham and Or­laith Ryan have of­fered scarce de­tails on what it is they’re work­ing on. But the FDA clear­ly likes what it sees.

The agency has grant­ed pri­or­i­ty re­view to SH-111, Shorla’s mys­tery can­di­date for the third-line treat­ment of adults and chil­dren with T-cell acute lym­phoblas­tic leukemia (T-ALL) and T-cell lym­phoblas­tic lym­phoma (T-LBL), the com­pa­ny said on Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.